Fig. 5From: Workflow-driven clinical decision support for personalized oncologyDetails of two simulated bevacizumab monotherapy schemes (dosage, frequency of administration and timepoints of administration). The treatment scheme details are extracted from European medicines agency (Avastin, INN - bevacizumab - WC500029271.pdf) and constitute the two suggested modes of bevacizumab administration for metastatic breast cancerBack to article page